Arch Therapeutics, Inc. (ARTH) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Framingham, MA, United States. El CEO actual es Terrence W. Norchi.
ARTH tiene fecha de IPO 2013-01-02, 8 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $444.00.
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
